Figure 1




cell number / field at day 7
0
200
400
600
800
1000
H27K15
Rituximab
H27K15 F(ab')2
Ritux. F(ab')2
mAb SM1.2 F(ab')2
2-4A5
GW2580
untreated
10 µg/ml mAb
1 µg/ml mAb
0.1 µg/ml mAb

Figure 2


Count
0
10^2
10^3
10^4
10^5
CD64
H27K15
Rituximab
Count
0
10^2
10^3
10^4
10^5
CD64
GW2580
No treatment




% reduction MedFi CD64
100
90
80
70
60
50
40
30
20
10
0
H27K15
H27K15 F(ab')2
2-4A5
9-4D2
GW2580
10 µg/ml
1 µg/ml
0.1 µg/ml

Figure 3


SSC
CD86
H27K15
SSC
CD86
rituximab



% increase CD86-bright SSC-low vs control
450
400
350
300
250
200
150
100
50
0
-50
H27K15
H27K15 F(ab')2
GW2580
10 µg/ml
1 µg/ml
0.1 µg/ml

Figure 4



pg/ml
IL-12p70
IL-10
IL-12p70 / IL-10 ratios
Donor 1
Donor 2
Donor 3
H27K15
rituximab
GW2580
no treatment

Figure 5



% reduction MCP-1
100
80
60
40
20
0
% reduction IL-6
100
80
60
40
20
0
Donor 1
Donor 2
Donor 3
H27K15 vs rituximab
GW2580 vs no treatment

Figure 6



MMP-9 ng/ml
Donor a
Donor b
Donor c
rituximab
H27K15
rituximab F(ab)'2
H27K15 F(ab)'2
no treatment
GW2580
0.1 µg/ml
1 µg/ml
10 µg/ml

Figure 7



% CD163+ macrophages
Donor A
Donor B
Donor C
untreated
GW2580
Rituximab
H27K15
Ritux. F(ab)'2
H27K15 F(ab)'2
0
5
10
15
20
2
4
6
8
0.1 µg/ml
1 µg/ml
10 µg/ml

Figure 8

M1-type (CD14+CD163-) / M2-type (CD163+CD14+) macrophage ratios among the CD14+ cell population at day 6




Figure 9



% CD1a+CD14-
60
40
20
0
donor I
donor II
donor III
donor IV
donor V
donor VI
rituximab
H27K15
untreated
% CD14+CD1a-
60
40
20
0
donor I
donor II
donor III
donor IV
donor V
donor VI

Figure 10




% of maximal proliferation
100
80
60
40
20
0
0.1
1.0
10.0
0.1
1.0
10.0
T-
T+
Antibody concentration (µg/mL)
H27K15
Rituximab
controls

Figure 11


A
40000
30000
20000
10000
0
[MCP1] pg/mL
CSF1
IL34
B
600000
400000
200000
0
RLU
CSF1
IL34
untreated
rituximab
H27K15